trial · primary record
Astegolimab
Chronic Obstructive Pulmonary Disease (COPD)
| Phase | Phase 3 |
|---|---|
| Status | COMPLETED |
| Sponsor | Unknown |
| Enrolment | 1380 |
| Primary completion | 2026-08-19 |
| Primary endpoint | Annualized Rate of Moderate and Severe COPD Exacerbations Over the 52-week Treatment Period |
| Registry ID | NCT05595642 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-10-28T13:39:20.367Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT05595642
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.